LUNG CANCER
Latest News
Latest Videos
More News
The immunotherapeutic vaccine OSE-2101 demonstrated a favorable 12-month survival rate as second- or third-line treatment of patients with HLA-A2-positive advanced non–small cell lung cancer, meeting the primary end point of overall survival in the phase III Atalante 1 study, according to a press release from the drug developer, OSE Immunotherapeutics, Inc.
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
The FDA has approved durvalumab in combination with standard-of-care chemotherapy as a frontline treatment for adult patients with extensive-stage small cell lung cancer.
In a Targeted Oncology case-based peer perspectives live discussion, Heather A. Wakelee, MD, discussed treatment with tyrosine kinase inhibitor treatment options for a real-world Hispanic patient with EGFR-mutant non–small cell lung cancer.<br />
A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Lung Cancer
In response to frequent and substantial changes in the treatment of non–small cell lung cancer in the frontline set­ting, the American Society of Clinical Oncology has partially updated its 2017 guide­line for the treatment of patients with stage IV disease without driver mutations.